BiotechTube
Home/Eisai/Keisuke Naito
KN

Keisuke Naito

Representative Director, President and COO

Eisai

Therapeutic Areas

NeurologyOncology

Eisai Pipeline

DrugIndicationPhase
Lecanemab (LEQEMBI)Alzheimer's DiseaseMarketed
Lenvatinib (LENVIMA)Renal Cell CarcinomaRegulatory Review
TaletrectinibROS1-Positive Non-Small Cell Lung CancerRegulatory Review
Lenvatinib + PembrolizumabVarious Solid TumorsPhase 3 / Marketed
Mycetoma Investigational DrugMycetomaClinical Development

Leadership Team at Eisai

HN
Haruo Naito
Former CEO, Architect of hhc Philosophy
KY
Koichi Yanagawa
Representative Director, Chairman and CEO
IC
Ivan Cheung
Former Chairman and CEO of Eisai Inc. (U.S.)
View full Eisai profile